Maximilian Will

Dr. Maximilian Will

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
MWMaximilian Will
Maximilian Will
CKChun Shing Kwok
Chun Shing Kwok
VNVinayak Nagaraja
Vinayak Nagaraja
RPRahul Potluri
Rahul Potluri
TWThomas W. Weiss
Thomas W. Weiss
KSKonstantin Schwarz
Konstantin Schwarz

23 November 2023 in Wiener klinische Wochenschrift
Verified
Journal Article
Open access
PDF file
RMRoya Anahita Mousavi
Roya Anahita Mousavi
GLGudrun Lamm
Gudrun Lamm
MWMaximilian Will
Maximilian Will
KSKonstantin Schwarz
Konstantin Schwarz
JMJulia Mascherbauer
Julia Mascherbauer
Summary: Significant sex-specific differences were described in the presentation, management and outcome of acute coronary syndrom (ACS) patients. Female ACS patients more often presented with noncardiac symptoms, which lead to significant time delays between symptom onset and treatment. Furthermore, multiple studies from various countries described that women with ACS were less likely to receive the medical or reperfusion therapy recommended by the respective guidelines, resulting in higher in-hospital mortality rates.The treating physicians and the patients need to be more aware of the described differences to ensure the best possible medical care for ACS patients, irrespective of sex.

19 February 2023 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
MWMaximilian Will
Maximilian Will
KSKonstantin Schwarz
Konstantin Schwarz
TWThomas Weiss
Thomas Weiss
GLGregor Leibundgut
Gregor Leibundgut
GLGudrun Lamm
Gudrun Lamm
CKChun Shing Kwok
Chun Shing Kwok
Coronary artery disease (CAD) is frequently encountered in patients evaluated for transcatheter aortic valve replacement (TAVR) due to severe aortic stenosis. The prognostic relevance of chronic total occlusions (CTOs) in this setting is poorly understood. We conducted a search of MEDLINE and EMBASE to identify studies evaluating patients who underwent TAVR and evaluated outcomes depending on the presence of coronary CTOs. Pooled analysis was performed to estimate the rate and risk ratio for mortality. Four studies involving 25,432 patients fulfilled the inclusion criteria. The follow up ranged from in‐hospital outcomes to 8‐years follow‐up. Coronary artery disease was present in 67.8% to 75.5% of patients in 3 studies which reported this variable. The prevalence of CTOs varied between 2% and 12.6% in this cohort. The presence of CTOs was associated with increase in length of stay (8.1 ± 8.2 vs. 5.9 ± 6.5, p < 0.01), cardiogenic shock (5.1% vs. 1.7%, p < 0.01), acute myocardial infarction (5.8% vs. 2.8%, p = 0.02) and acute kidney injury (18.6% vs. 13.9%, p = 0.048). The pooled 1‐year death rate revealed 41 deaths in 165 patients in the CTO group and 396 deaths in 1663 patients with no CTO ((24.8%) vs. (23.8%)). The meta‐analysis of death with CTO versus no CTO showed a nonsignificant trend toward increased mortality with CTOs (risk ratio 1.11 95% CI 0.90–1.40, I2 = 0%). Our analysis suggests that concomitant CTO lesions in patients undergoing TAVR are common, and its presence was associated with increased in‐hospital complications. However, CTO presence by itself was not associated with increased long‐term mortality, only a nonsignificant trend toward an increased risk of death in patients with CTO was found. Further studies are warranted to assess the prognostic relevance of CTO lesion in TAVR patients.

27 September 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
MWMaximilian Will
Maximilian Will
KSKonstantin Schwarz
Konstantin Schwarz
SASimone Aufhauser
Simone Aufhauser
GLGregor Leibundgut
Gregor Leibundgut
ESElisabeth Schmidt
Elisabeth Schmidt
\W\R\Nmaximilian Will
\R\Nmaximilian Will
Background: The benefit of chronic total occlusion (CTO)-percutaneous coronary intervention (PCI) is controversial because of a lack of high-quality evidence. We aim to evaluate the impact of CTO-PCI on symptoms, quality of life and mortality.Methods: We conducted a retrospective single center study of patients with CTO-PCI in a tertiary center in Austria. The study outcomes were Canadian Cardiovascular Society (CCS) angina score, quality of life measured by Seattle Angina Questionnaire (SAQ), and death at median follow up for patients with successful vs. failed CTO-PCI.Results: A total of 300 patients underwent CTO-PCI for coronary artery disease, of which 252 (84%) were technically successful with median follow up of 3.4 years. There were no significant differences in in-hospital or all-cause mortality, major adverse cardiovascular event, or stent-related complications between the groups of failed and successful CTO-PCI. Among patients with successful CTO-PCI there was a significant improvement in CCS score, which was not found for the group with failed CTO-PCI. Successful reopening was associated with significant benefits of the SAQ domains of angina with stressful activity [3.7 ± 0.9 vs. 3.1 ± 0.5, p = 0.004, use of nitrates (4.7 ± 0.5 vs. 3.0 ± 1.0) p = 0.005] and satisfaction from angina relief (4.4 ± 1.1 vs. 3.6 ± 1.4 p < 0.001).Conclusion: While there was no significant difference in mortality, successful CTO-PCI was associated with greater reduction in angina and the use of nitrates compared to unsuccessful CTO-PCI.

11 September 2024 in Diseases
Verified
Journal Article
Open access
PDF file
KSKonstantin Schwarz
Konstantin Schwarz
IBIda Straume Bah
Ida Straume Bah
MWMaximilian Will
Maximilian Will
CKChun Shing Kwok
Chun Shing Kwok
JMJulia Mascherbauer
Julia Mascherbauer
Josip Andelo BorovacJosip Andelo Borovac
Josip Andelo Borovac
Background/Objectives: Renal artery stenosis (RAS) is associated with coronary artery disease (CAD), exacerbation of arterial hypertension, and progression to heart failure, but remains frequently unrecognized in clinical practice. Methods: We conducted a systematic review and meta-analysis of studies by pooling data of patients undergoing CAG due to suspected or stable CAD that received a bilateral renal artery angiography. Results: A total of 31 studies with 31,689 patients were included (mean age 63.2 ± 8.7 years, 20.9% were female). Overall, 13.4% (95%CI 10.5–16.7%) of patients undergoing coronary angiography had significant RAS, with 6.5% (95% CI 4.5–8.9%) and 3.7% (95%CI 2.5–5.2%) having severe and bilateral RAS. The mean weighted proportion of patients with three-vessel coronary disease (3VD) was 25.1 (95%CI 19.6–30.9%) while 4.2% (95%CI 2.6–6.2%) had left main (LM) coronary disease. Patients with RAS compared to those without RAS were significantly older (mean difference, MD 4.2 years (95%CI 3.8–4.6)). The relative risk of RAS was greater for the female sex (risk ratio, 95%CI; RR 1.3, 1.03–1.57), presence of diabetes (RR 1.2, 1.10–1.36), arterial hypertension (RR 1.3, 1.21–1.46), dyslipidemia (RR 1.1, 1.06–1.14), peripheral artery disease (PAD) (RR 2.1, 1.40–3.16), chronic kidney disease (CKD) (RR 2.6, 2.04–3.37), 3VD (RR 1.6, 1.30–1.87), and LM disease (RR 1.8, 1.28–2.47). Smoking had a neutral effect on the risk of RAS occurrence (RR 1.0, 0.94–1.06). Conclusions: RAS is common in patients undergoing coronary angiography. CKD, PAD, older age, and severe CAD were among the strongest predictors for the presence of significant RAS.

Verified
Journal Article
Open access
PDF file
CKChun Shing Kwok
Chun Shing Kwok
AQAdnan I. Qureshi
Adnan I. Qureshi
Josip Andelo BorovacJosip Andelo Borovac
Josip Andelo Borovac
MWMaximilian Will
Maximilian Will
KSKonstantin Schwarz
Konstantin Schwarz
Gregory LipGregory Lip
Gregory Lip
Background: The stroke–heart syndrome refers to incident cardiac complications post stroke. This study aims to evaluate the stroke–heart syndrome by determining the rate and predictors of readmission for cardiac disease within 30 days of hospitalization for cerebral infarction. Methods: Data from the United States Nationwide Readmissions Database (2018 to 2020) were analyzed to identify rates and factors associated with 30-day readmissions for heart disease following cerebral infarction, excluding patients with atrial fibrillation, heart failure and myocardial infarction during admission with cerebral infarction. Results: There were 3,115,850 hospital admissions for cerebral infarction, and 75,440 admissions (2.4%) were readmitted with new onset cardiac events within 30 days of discharge. This included 36,310 (1.4%) readmissions for heart failure, 35,900 (1.1%) readmissions for atrial fibrillation, 17,465 (0.5%) readmissions for acute myocardial infarction, 810 (0.03%) readmissions for ventricular arrhythmias and 700 (0.02%) readmissions for Takotsubo syndrome. Readmitted patients were older (median age of 73 years vs. 68 years, p < 0.001) and had a longer length of stay for initial admission (median of 4 days vs. 3 days, p < 0.001). The most significant predictors of readmission were elective admission (OR 2.00, 95%CI 1.89–2.13, p < 0.001), cancer (OR 1.91, 95%CI 1.81–2.01, p < 0.001), chronic kidney disease (OR 1.80, 95%CI 1.73–1.87, p < 0.001), previous myocardial infarction (OR 1.59, 95%CI 1.50–1.69, p < 0.001) and liver failure (OR 1.34, 95%CI 1.06–1.68, p = 0.013). Palliative care was linked to a reduced odds of readmission (OR 0.36, 95%CI 0.31–0.41, p < 0.001). Conclusions: New cardiac-related hospital readmissions within 30 days after ischemic stroke occur in 2.4% of patients, with elective admission and cancer being a strong predictor of readmissions.